Not enough data
Mandy Jackson's coverage focuses on the healthcare and pharmaceutical industry, particularly on drug development, FDA approvals, and biopharmaceutical companies. Additionally, she covers financial aspects related to these sectors.
Given her focus on press releases and private sector announcements, Mandy would likely be responsive to pitches that provide exclusive insights into new drug developments or financial activities within the healthcare and pharmaceutical industries. She may also be interested in expert commentary regarding regulatory changes impacting drug development or financial trends affecting biopharmaceutical companies.
While no specific geographic focus is mentioned for Mandy's coverage area, it’s important to note that her articles cover global developments in the healthcare and pharmaceutical sectors as well as finance-related topics relevant to these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jul By, Mandy Jackson
Public Company Edition: Abivax raised $920m and Definium brought in $805m from follow-on public offerings, continuing a trend of large FOPOs after positive data. Also, Ligand sold $700m worth of notes, PTC priced a $500m note offering and Dyne expanded its debt facility to $400m.
By: Mandy Jackson, Jul By
With strong revenue growth and no big near-term loss of exclusivity, Johnson & Johnson's global head of business development Nauman Shah said the company can focus on smaller, earlier deals.
Eight drugmakers went public on Western exchanges during the second quarter, up from six in Q1, and the amount raised more than doubled to $3.8bn versus $1.8bn in Q1.
Vertex will pay $85 per share for Crinetics, which is double the company's July 6 closing stock price, to acquire what it sees as a blockbuster endocrinology franchise.
By: Mandy Jackson, Jul By
Scrip spoke with Bayer executives who head its Co.Lab incubators and focus on oncology business development, Friedemann Janus and Deepa Talpade, about early-stage dealmaking.
By: Mandy Jackson
Scrip spoke with Paris Panayiotopoulos, senior managing director at Blackstone Life Sciences, about the investment firm’s role in helping big pharma fund their rapidly expanding R&D pipelines.
Second-quarter 2026 data show biopharma venture capital fundraising surged to its highest level since Q1 2021 with a 68% rise in $100m-plus rounds, led by Isomorphic's $2.1bn financing.
By: Mandy Jackson, Jul By
Scrip spoke with Gilead SVP Devang Bhuva, who is moving from corporate development to a finance leadership role, about the strategies underlying the company's recent acquisitions.
By: Mandy Jackson, Jul By
Spero raised $105m, to be repaid by milestone fees and royalties from its newly approved, GSK-partnered antibiotic Utebzi. It will fund a Phase II trial in IgG4-related disease for SP001, in-licensed from Innovent.
By: Mandy Jackson, Jul By
Private Company Edition: Chai Discovery raised $400m in series C venture capital and AdvanCell closed a $315m series D financing, while Mighty Therapeutics secured up to $150m in debt and VC cash. Fore Biotherapeutics raised $67.4m, bringing its series D-2 total to $110m.
